AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11672943
Drug: Flunitrazepam 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 1.25 mg (fast onset)
Trial: 11672943
Drug: Flunitrazepam 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 0.4 mg (slow onset)
Trial: 11672943
Drug: Flunitrazepam 2
RxNorm normalized name: flunitrazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 2 mg (fast onset)
Trial: 9141914
Drug: Dopexamine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopexamine (all doses)
Trial: 7944696
Drug: Heparin-coated bypass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated bypass circuits with an uncoated cardiotomy reservoir
Trial: 7944696
Drug: Heparin-coated bypass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated bypass circuits
Trial: 30479531
Drug: Concurrent Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Training (CT) - high-intensity intermittent training plus strength training, performed twice weekly for 12 weeks.
Trial: 30479531
Drug: Strength Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength Training (ST) - strength training sessions only, performed twice weekly for 12 weeks.
Trial: 28578652
Drug: CROSS protocol
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CROSS protocol (Carboplatin and Paclitaxel with concurrent radiotherapy, 41.4Gy/23Fr, over 5 weeks)
Trial: 28578652
Drug: Standard perioperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard perioperative chemotherapy regimen (not explicitly detailed in the abstract)
Trial: 12698181
Drug: irinotecan 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan 200 mg x m(‐2) on day 1 plus raltitrexed 3 mg x m(‐2) on day 2 (arm B)
Trial: 12698181
Drug: raltitrexed 3
RxNorm normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: raltitrexed 3 mg x m(‐2) on day 1 (arm A)
Trial: 10392322
Drug: Sibrafiban (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibrafiban (oral administration, once or twice daily for up to 28 days)
Trial: 10392322
Drug: Sibrafiban (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibrafiban (once-daily dosing)
Trial: 10392322
Drug: Sibrafiban (twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibrafiban (twice-daily dosing)
Trial: 10392322
Drug: Sibrafiban (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibrafiban (oral administration)
Trial: 8694022
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (6 g ethyl ester daily)
Trial: 8694022
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (6 g ethyl ester daily)
Trial: 8694022
Drug: Safflower oil
RxNorm normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower oil (6 g ethyl ester daily)
Trial: 27746565
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of 10mg ephedrine
Trial: 27746565
Drug: Crystalloid preloading
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid preloading with ringer lactate 15 mL.kg‐1
Trial: 18179661
Drug: Rimonabant 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant 20 mg/day for 2 years
Trial: 15731987
Drug: No exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No exposure to known teratogenic drugs (control group)
Trial: 10944479
Drug: Lycopene (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene (15 mg daily) for 26 days
Trial: 10944479
Drug: Lutein (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein (15 mg daily) for 26 days
Trial: 26231819
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) delivered via videoconference (VTC)
Trial: 26231819
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT) delivered in person (IP)
Trial: 25264948
Drug: Low-dose insulin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose insulin (0.05 U/kg per hour)
Trial: 25264948
Drug: Standard-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose insulin (0.1 U/kg per hour)
Trial: 1355791
Drug: Ronactolol 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ronactolol 30 mg
Trial: 1355791
Drug: Ronactolol 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ronactolol 60 mg
Trial: 1355791
Drug: Ronactolol 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ronactolol 120 mg
Trial: 3899672
Drug: Prazosin 4
RxNorm normalized name: prazosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin 4 mg/day for 6 weeks
Trial: 3899672
Drug: Alphamethyldopa 250-750
RxNorm normalized name: Alphamethyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alphamethyldopa 250-750 mg/day for 6 weeks
Trial: 25225424
Drug: Aprepitant (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 to 4), granisetron (2 mg orally on days 1 to 4), and dexamethasone (4 mg orally on day 1 and 2 mg orally on days 2 to 3)
Trial: 25225424
Drug: Placebo, granisetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, granisetron (2 mg orally on days 1 to 4), and dexamethasone (8 mg orally on day 1 and 4 mg orally on days 2 to 3)
Trial: 22287757
Drug: Modified intermediate-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified intermediate-dose cytarabine (mIDAC; Ara-C at a dose of 1.0 g/m(2) every 12 hours for 5 days)
Trial: 22287757
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (HDAC; Ara-C at a dose of 2.0 g/m(2) every 12 hours for 5 days)
Trial: 22287757
Drug: Modified intermediate-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified intermediate-dose cytarabine (mIDAC)
Trial: 17660839
Drug: Chemotherapy or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy or autologous transplantation
Trial: 15468717
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy (angiotensin‐converting enzyme inhibitors, nitrates, diuretics, beta‐adrenoblockers; 27.6% received digoxin, disaggregatory agents)
Trial: 9233865
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g once daily for 14 days)
Trial: 9233865
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg twice daily for 21 days)
Trial: 3606073
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (50 g immediately before vancomycin infusion, followed by 15 g at 2, 4, 6, and 8 hours)
Trial: 27778191
Drug: Control (statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (statin therapy only)
Trial: 19735400
Drug: Dobutamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine infusion at 4 microg x kg(‐1) x min(‐1)
Trial: 19735400
Drug: Dobutamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine infusion at 6 microg x kg(‐1) x min(‐1)
Trial: 15801953
Drug: Good response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Good response group (GRG) with <25% blasts in bone marrow within the first 2 weeks of treatment
Trial: 15801953
Drug: Daunorubicin included
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin included in induction therapy
Trial: 10235017
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for asymptomatic carotid artery disease with 60% or greater linear stenosis
Trial: 10235017
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for symptomatic carotid artery disease with 50% or greater linear stenosis
Trial: 786667
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg mephenoxalone
Trial: 786667
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg paracetamol
Trial: 786667
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 400 mg mephenoxalone and 900 mg paracetamol
Trial: 25530068
Drug: Pregabalin (PGB)
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin (PGB) plus oral morphine
Trial: 25530068
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) plus oral morphine
Trial: 25781235
Drug: nateglinide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nateglinide (120 mg three times a day)
Trial: 25781235
Drug: acarbose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acarbose (50 mg three times a day)
Trial: 23254437
Drug: Quinine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine plus primaquine (30 mg/day for 14 days)
Trial: 23254437
Drug: Dihydroartemisinin-piperaquine plus
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine plus primaquine (30 mg/day for 14 days)
Trial: 23254437
Drug: Artesunate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (200 mg dose followed by 100 mg/day for 6 days)
Trial: 16458259
Drug: Testosterone (sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (sublingual administration, single dose)
Trial: 15123479
Drug: School-based care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based care group (daily inhaled corticosteroids provided through the school)
Trial: 12141848
Drug: Lecture-style educational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecture-style educational program (L)
Trial: 12141848
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (I and L)
Trial: 9450159
Drug: Pivagabine 1800
RxNorm normalized name: pivagabine
DrugBank: Pivagabine (DB12951)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivagabine 1800 mg/d for four weeks
Trial: 7949496
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus famotidine (50 mg/24 h, 25th‐75th percentiles = 40‐55 mg)
Trial: 7949496
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion famotidine (42 mg/24 h, 25th‐75th percentiles = 42‐52 mg)
Trial: 31836930
Drug: Vedolizumab 300
RxNorm normalized name: vedolizumab 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab 300 mg at Weeks 0, 2, and 6 (induction phase)
Trial: 31836930
Drug: Vedolizumab 300
RxNorm normalized name: vedolizumab 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab 300 mg at Week 14 and every 8 weeks until Week 54 (maintenance phase)
Trial: 28510773
Drug: Video game
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Video game play plus occlusion therapy (1 hour of video game play per day for the first month plus 6 hours of occlusion therapy per day)
Trial: 28510773
Drug: Occlusion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusion therapy alone (6 hours per day)
Trial: 26077603
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch (6 weeks)
Trial: 26077603
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch (6 weeks)
Trial: 23700731
Drug: Low-dose daily
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose daily de-escalatory administration of tadalafil for 2 months
Trial: 23700731
Drug: On-demand medication
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand medication of tadalafil for 2 months
Trial: 20416893
Drug: Indomethacin 25
RxNorm normalized name: indomethacin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 25 mg orally, 3 times daily for 7 days preoperatively
Trial: 20416893
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving oral placebo
Trial: 11776507
Drug: 25 microg
RxNorm normalized name: Digoxin 125 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 microg estradiol vaginal tablet
Trial: 11776507
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g conjugated estrogen cream
Trial: 8090608
Drug: Beta 2-agonist
RxNorm normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta 2-agonist (terbutaline, 500 micrograms via nebuhaler)
Trial: 8090608
Drug: Beta 2-agonist
RxNorm normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta 2-agonist (terbutaline)
Trial: 2899772
Drug: 1‐hour intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‐hour intravenous infusion of 1.5 MU of streptokinase
Trial: 2899772
Drug: 160 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg/day enteric‐coated aspirin for one month
Trial: 2899772
Drug: Streptokinase and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase and aspirin
Trial: 23358966
Drug: Individualized dosing
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized dosing of EC‐Asnase (ID)
Trial: 23358966
Drug: Fixed dosing
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dosing of EC‐Asnase (FD)
Trial: 15871635
Drug: Valganciclovir (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir (900 mg once daily)
Trial: 10994883
Drug: Continuous passive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous passive motion (CPM) for 5 consecutive hours per day plus physical therapy
Trial: 8793703
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists or angiotensin converting enzyme inhibitors (n = 266)
Trial: 8793703
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration (n = 116)
Trial: 1465059
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (0.7 +/- 0.1 g/kg/day)
Trial: 1465059
Drug: Vegetarian soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetarian soy diet (0.71 +/- 0.36 g/kg ideal body weight/day)
Trial: 3871797
Drug: Enteric-coated erythromycin
RxNorm normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated erythromycin pellets (250 mg base)
Trial: 3871797
Drug: Erythromycin ethylsuccinate
RxNorm normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin ethylsuccinate (400 mg base equivalent)
Trial: 3622938
Drug: Cisapride (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (20 mg p.o.)
Trial: 25978046
Drug: Melissa officinalis
RxNorm normalized name: melissa officinalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melissa officinalis extract containing 500 mg rosmarinic acid (fasted state)
Trial: 25978046
Drug: Melissa officinalis
RxNorm normalized name: melissa officinalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melissa officinalis extract containing 500 mg rosmarinic acid (fed state)
Trial: 25978046
Drug: Melissa officinalis
RxNorm normalized name: melissa officinalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melissa officinalis extract containing 500 mg rosmarinic acid
Trial: 19114860
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) with protease inhibitor dose escalation
Trial: 15663123
Drug: Carbohydrate solution
RxNorm normalized name: phosphorated carbohydrate solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate solution (25 g carbohydrates)
Trial: 9150807
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vigabatrin (VGB) add-on treatment
Trial: 7919566
Drug: Tacrine (cholinesterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine (cholinesterase inhibitor)
Trial: 3585450
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine sulfate (MSC)
Trial: 31843338
Drug: Chemotherapy (182
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (182 patients)
Trial: 31843338
Drug: Reduced high‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced high‐dose volume radiotherapy (111 patients)
Trial: 30989173
Drug: Augmentor software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentor software package for image augmentation
Trial: 27900942
Drug: GFR <
RxNorm normalized name: Glomerular Filtration Rate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFR < 45 mL/min/1.73 m2
Trial: 27900942
Drug: GFR ≥
RxNorm normalized name: Glomerular Filtration Rate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFR ≥ 90 mL/min/1.73 m2
Trial: 26322635
Drug: 30‐mL balloon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30‐mL balloon for a maximum of 12 hours
Trial: 26322635
Drug: 30‐mL balloon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30‐mL balloon for a maximum of 24 hours
Trial: 26322635
Drug: 80‐mL balloon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80‐mL balloon for a maximum of 12 hours
Trial: 26322635
Drug: 80‐mL balloon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80‐mL balloon for a maximum of 24 hours
Trial: 26322635
Drug: Higher balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher balloon volume (80‐mL) and longer ripening time (24 hours)
Trial: 16879332
Drug: Conventional buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional buccal infiltration (CBi)
Trial: 16879332
Drug: Periodontal ligament
RxNorm normalized name: human ligament preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal ligament injection (PDLi)
Trial: 11421896
Drug: Nedocromil sodium,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium, two puffs twice daily, 0.002 g/puff
Trial: 11421896
Drug: Placebo, two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, two puffs twice daily
Trial: 9508754
Drug: Diacarb administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacarb administered after the proposed protocols
Trial: 8514653
Drug: Once-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing of netilmicin (6 mg/kg body weight)
Trial: 8514653
Drug: Thrice-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-daily dosing of netilmicin (6 mg/kg body weight)
Trial: 8514653
Drug: Thrice-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-daily dosing of netilmicin
Trial: 3734289
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 2.2 or 4.4 mg of azelastine
Trial: 3734289
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose therapy with 4.4 mg of azelastine for 21 days
Trial: 30531384
Drug: L‐dopa ON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐dopa ON
Trial: 30531384
Drug: L‐dopa OFF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐dopa OFF
Trial: 30531384
Drug: Practice dose
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practice dose and acquisition rate
Trial: 25917017
Drug: Electrical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical stimulation therapy on the suprahyoid muscles (SM group, n = 66)
Trial: 25917017
Drug: Electrical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical stimulation therapy with electrodes on both suprahyoid and infrahyoid muscles (SI group, n = 66)
Trial: 19751115
Drug: Amlodipine/valsartan (10/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan (10/160 mg o.d.)
Trial: 19751115
Drug: Amlodipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (10 mg o.d.)
Trial: 16954960
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg for 14 days)